India’s Rise as a Global Hub for Affordable Weight-Loss Drugs
Weight-loss medications are becoming significantly more accessible in India, with prices plummeting to as low as £10 (approximately $13) per month following the expiration of a key patent. This development contrasts sharply with the costs in countries like the UK, where private prescriptions can exceed £200 per injection pen.
Patent Expiration and the Surge of Generics
Novo Nordisk’s patent on semaglutide, the active ingredient in popular drugs like Wegovy and Ozempic, expired in India on Friday, March 21, 2026. This expiration triggered the immediate launch of generic versions by at least seven Indian pharmaceutical companies. As reported by CNBC, these generic alternatives are undercutting the original price by up to 80%.
Price Comparison: Generic vs. Brand-Name Semaglutide
Sun Pharmaceutical launched a generic semaglutide for approximately 750 rupees ($8) per weekly injection, equating to around 3,400 rupees ($43) per month. This is considerably lower than Novo Nordisk’s retail price in India, which ranges from 8,800 to 10,000 rupees ($111-$126) depending on the dosage.
Other companies have as well entered the market with varying price points:
- Eris Life Sciences: Sundae, approximately £10.33 ($13) per month
- Glenmark: £10.39 – £14.08 ($13-$18) per month
- Alkem Laboratories: Semasize, Obesama and Hepaglide, starting at £14.41 ($18) per month
- Zydus Lifesciences: Alterme, Mashema and Semaglyn, around £17.60 ($22) per month
- Torrent Pharmaceuticals: Sembolic and Semalix (oral tablets and injections), at least £31.24 ($39) per month
- Dr. Reddy’s Laboratories: 2mg and 4mg for diabetes treatment, £33.62 ($42) per month
- Sun Pharmaceutical: Noveltreat (weight loss) and Sematrinity (type 2 diabetes), £28.80 – £65 ($36-$82) per month
Global Implications and Patent Expiry Dates
Novo Nordisk’s patent on semaglutide is still valid in the UK until 2031. However, it is set to expire in Canada, China, and Brazil later in 2026, potentially leading to increased competition and lower prices in those markets as well. Reuters reports that over 40 Indian firms are preparing to launch more than 50 products in the coming weeks.
Safety Concerns and Regulatory Oversight
Experts caution against purchasing cheaper medication from abroad without approval from regulatory bodies like the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. The Daily Mail quotes Dr. Leyla Hannbeck, chief executive of the Independent Pharmacies Association, warning about the risks of obtaining unverified products.
“We would never recommend people going abroad and obtaining them via whatever websites, because you never know if it’s a legitimate product or what you’re going to get,” Dr. Hannbeck stated. “Wait for them to be approved for apply in the UK by the MHRA. Then you will be 100 per cent sure that you’re getting it from a legitimate place and that they’re causing you no harm.”
Potential for Misuse and Regulatory Tightening
The increased availability of affordable semaglutide raises concerns about potential misuse, including direct pharmacy purchases, diversion through distributors, and use for cosmetic or lifestyle purposes. Fierce Pharma highlights concerns from industry consultant Salil Kallianpur, who suggests this could lead to unmanaged side effects and eventual regulatory tightening.
Novo Nordisk’s Response
Novo Nordisk is closely monitoring the competitive landscape in India and will evaluate the pricing and market strategies of its rivals before responding. The Economic Times reports that the company’s India head, Vikrant Shrotriya, stated they will remain “vigilant” and assess the situation before taking action.
Recent Market Trends and Usage
Semaglutide became available as a weight-loss aid in the UK in 2018, with approximately 10.2 million prescriptions issued in the past five years. Estimates suggest that up to 1.6 million people in Britain have used weight-loss drugs like Wegovy or Mounjaro in the past year, with the majority accessing them privately.
Potential Risks Associated with Semaglutide
Although semaglutide has been hailed as a breakthrough in obesity treatment, it is not without risks. A study published in the British Journal of Ophthalmology suggests a potential increased risk of ischemic optic neuropathy (ION), a condition that can cause sudden and permanent vision loss.